STAAR Surgical Co. 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 29, 1995, and the nine-month period ended September 29, 1995. STAAR Surgical Company is a Delaware corporation engaged in the design, manufacture, and marketing of intraocular lenses (IOLs) and related surgical instruments for cataract surgery. The company operates globally with significant export sales to Europe, South Africa, South America, Australia, and Japan.
Key Financial Metrics
| Metric | Nine Months Ended Sep 29, 1995 | Nine Months Ended Sep 30, 1994 |
|---|---|---|
| Total Revenues | $24,713,890 | $19,273,189 |
| Net Income | $5,524,829 | $4,138,458 |
| Gross Margin | 75.9% | 77.2% |
| Operating Income | $5,348,095 | $3,607,267 |
| Cash from Operations | $3,915,966 | $893,932 |
| Cash and Equivalents (End of Period) | $4,100,066 | $1,010,418 |
| Total Debt (Current + Long Term) | $4,080,746 | $2,363,980 |
| Current Ratio | 3.3:1 | 3.4:1 (Dec 30, 1994) |
| Net Working Capital | $16,275,422 | $14,165,498 (Dec 30, 1994) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 28.2% year-over-year, driven primarily by expanding international sales and continued U.S. product acceptance. Royalty income was $0 for the current period compared to $893,280 in the prior year.
- Profitability: Net income increased 33.5% to $5.5 million. Operating income rose 48.3% due to revenue growth outpacing expense increases.
- Cost Structure: Cost of sales as a percentage of revenue increased to 24.1% from 22.8%, attributed to reduced pricing in the domestic market. Gross margin consequently declined slightly.
- Expenses: Marketing and selling expenses increased 33.7% in absolute terms (30.7% of revenue) due to international staffing and advertising. General and administrative expenses decreased as a percentage of revenue (14.4% vs 18.7%) due to cost controls.
- Liquidity: Cash and cash equivalents increased by $896,179 during the period. The company utilized $1.5 million of working capital to repurchase approximately 176,500 shares of common stock.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue profitability and believes future cash flow needs will be met by operations or debt financing. Royalty income is expected to be minimal for the remainder of 1995 but is anticipated in 1996.
- R&D Strategy: The company plans to maintain R&D spending at approximately 10% of revenues for product development and approval.
- Legal Contingencies:
- Alcon Laboratories: STAAR filed a lawsuit against Alcon regarding breach of contract and specific performance related to Patent No. 4,573,998. Alcon previously sued STAAR regarding the same patent. The Delaware court granted STAAR's motion to transfer the action to California.
- Allergan Medical Optics: A U.S. District Court ruled that STAAR's antitrust action against Allergan should proceed and lifted the stay on discovery regarding Patent No. 4,681,102 (the "102 Patent"). The court confirmed Microtech as the owner of this patent. STAAR believes the 102 Patent will be deemed invalid and unenforceable.
- Tax Position: The company expects to record an income tax benefit in the fourth quarter by utilizing net operating loss carryforwards to recognize a deferred tax asset.
Investor Verification Checklist
- Verify the sustainability of international revenue growth given the absence of royalty income in the current period.
- Monitor the outcome of the litigation with Alcon Laboratories and Allergan Medical Optics, specifically regarding the validity and ownership of key patents (Nos. 4,573,998 and 4,681,102).
- Assess the impact of domestic price reductions on future gross margins.
- Confirm the company's ability to maintain R&D spending at 10% of revenue while managing marketing costs.
- Review the status of the stock repurchase program, which allows for the buyback of up to 1,000,000 shares.